Not only for melanoma. Subcutaneous pseudoprogression in lung squamous-cell carcinoma treated with nivolumab: A case report

Michal Sarfaty, Assaf Moore, Elizabeth Dudnik, Nir Peled*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Rationale: Pseudoprogression, that is, initial tumor growth followed by subsequent tumor regression, has been well described for immunomodulation therapy in melanoma patients. This phenomenon is not well defined in lung cancer. Nivolumab, an anti-PD-1 monoclonal antibody, was recently approved for nonsmall cell lung cancer (NSCLC) as a second-line therapy. Patient concerns and diagnosis: We present a patient with squamous NSCLC, suffering from multiple bone and subcutaneous metastases. Interventions: The patient was treated with nivolumab. Outcomes: A subcutaneous lesion in her upper back grew substantially after the first cycle of nivolumab, and later regressed, with marked improvement in all cancer sites. Lessons: Such pseudoprogression may serve to predict subsequent clinical response.

Original languageEnglish
Article number5951
JournalMedicine (United States)
Volume96
Issue number4
DOIs
StatePublished - 2017

Keywords

  • Lung cancer
  • Nivolumab
  • Pseudoprogression
  • Squamous-cell carcinoma

Fingerprint

Dive into the research topics of 'Not only for melanoma. Subcutaneous pseudoprogression in lung squamous-cell carcinoma treated with nivolumab: A case report'. Together they form a unique fingerprint.

Cite this